Insulin lispro

Drug Profile

Insulin lispro

Alternative Names: Humalog N; LY 275585; Lys-B28, Pro-B29; Lyspro

Latest Information Update: 12 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Eli Lilly
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Tyrosine aminotransferase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Diabetes mellitus

Most Recent Events

  • 27 Jun 2017 Eli Lilly withdrew a pharmacokinetics phase I trial prior to enrolment for Type-2 diabetes mellitus (Treatment-experienced) in USA and Germany due to change in clinical strategy (SC) (NCT02623465)
  • 27 Jun 2017 Eli Lilly withdraws prior to enrolment a pharmacokinetics phase I trial for Type-1 diabetes mellitus (Treatment-experienced) in Germany (SC) (NCT02623452)
  • 11 Jan 2016 Eli Lilly in-licenses OmniPod® tubeless insulin delivery system from Insulet Corporation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top